CXCR4 and plasma cell myeloma: Ulocuplumab, a monoclonal anti-CXCL4 antibody, as well as neutralization of SDF1 by Olaptesed-pegol (PEGylated mirror-image l-oligonucleotide), inhibit myeloma cell dissemination and suppress the CXCR4-driven EMT-like [70].